Marker Therapeutics Inc. (MRKR)
Marker Therapeutics Statistics
Share Statistics
Marker Therapeutics has 10.71M shares outstanding. The number of shares has increased by 20.07% in one year.
| Shares Outstanding | 10.71M |
| Shares Change (YoY) | 20.07% |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | 0.83% |
| Shares Floating | 7.47M |
| Failed to Deliver (FTD) Shares | 160 |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 400.02K, so 3.74% of the outstanding shares have been sold short.
| Short Interest | 400.02K |
| Short % of Shares Out | 3.74% |
| Short % of Float | 4.86% |
| Short Ratio (days to cover) | 6.15 |
Valuation Ratios
The PE ratio is -2.6 and the forward PE ratio is -0.59. Marker Therapeutics's PEG ratio is 0.07.
| PE Ratio | -2.6 |
| Forward PE | -0.59 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Marker Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.36, with a Debt / Equity ratio of 0.
| Current Ratio | 6.36 |
| Quick Ratio | 6.36 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,318.2B |
| Profits Per Employee | $-2.15M |
| Employee Count | 5 |
| Asset Turnover | 0.3 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 49.95B |
| Effective Tax Rate | -0.47% |
Stock Price Statistics
The stock price has increased by -71.71% in the last 52 weeks. The beta is 1.54, so Marker Therapeutics's price volatility has been higher than the market average.
| Beta | 1.54 |
| 52-Week Price Change | -71.71% |
| 50-Day Moving Average | 1.37 |
| 200-Day Moving Average | 2.99 |
| Relative Strength Index (RSI) | 46.17 |
| Average Volume (20 Days) | 134.11K |
Income Statement
In the last 12 months, Marker Therapeutics had revenue of 6,591.1B and earned -10.73M in profits. Earnings per share was -1.19.
| Revenue | 6,591.1B |
| Gross Profit | 6,591.1B |
| Operating Income | -11,118.4B |
| Net Income | -10.73M |
| EBITDA | -11,118.4B |
| EBIT | -4.53M |
| Earnings Per Share (EPS) | -1.19 |
Balance Sheet
The company has 19.19M in cash and 0 in debt, giving a net cash position of 19.19M.
| Cash & Cash Equivalents | 19.19M |
| Total Debt | 0 |
| Net Cash | 19.19M |
| Retained Earnings | -447,017.2B |
| Total Assets | 22,022.9B |
| Working Capital | 18,558.4B |
Cash Flow
In the last 12 months, operating cash flow was -10,910.3B and capital expenditures 0, giving a free cash flow of -10,910.3B.
| Operating Cash Flow | -10,910.3B |
| Capital Expenditures | 0 |
| Free Cash Flow | -10,910.3B |
| FCF Per Share | -1214930.12 |
Margins
Gross margin is 100%, with operating and profit margins of -168.69% and 0%.
| Gross Margin | 100% |
| Operating Margin | -168.69% |
| Pretax Margin | -162.06% |
| Profit Margin | n/a |
| EBITDA Margin | -168.69% |
| EBIT Margin | -168.69% |
| FCF Margin | -165.53% |
Dividends & Yields
MRKR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for MRKR is $12.5, which is 977.6% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.5 |
| Price Target Difference | 977.6% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Jan 27, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Jan 27, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -28.71 |
| Piotroski F-Score | 3 |